Display options
Cite
Lin HT, Masaki H, Yamaguchi T, et al. An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils. Mol Ther Methods Clin Dev. 2015;2:15046doi: 10.1038/mtm.2015.46.
Lin, H. T., Masaki, H., Yamaguchi, T., Wada, T., Yachie, A., Nishimura, K., Ohtaka, M., Nakanishi, M., Nakauchi, H., & Otsu, M. (2015). An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils. Molecular therapy. Methods & clinical development, 215046. https://doi.org/10.1038/mtm.2015.46
Lin, Huan-Ting, et al. "An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils." Molecular therapy. Methods & clinical development vol. 2 (2015): 15046. doi: https://doi.org/10.1038/mtm.2015.46
Lin HT, Masaki H, Yamaguchi T, Wada T, Yachie A, Nishimura K, Ohtaka M, Nakanishi M, Nakauchi H, Otsu M. An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils. Mol Ther Methods Clin Dev. 2015 Dec 09;2:15046. doi: 10.1038/mtm.2015.46. eCollection 2015. PMID: 26682238; PMCID: PMC4674005.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Methods Clin Dev. 2015 Dec 09;2:15046. doi: 10.1038/mtm.2015.46. eCollection 2015.

An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils.

Molecular therapy. Methods & clinical development

Huan-Ting Lin, Hideki Masaki, Tomoyuki Yamaguchi, Taizo Wada, Akihiro Yachie, Ken Nishimura, Manami Ohtaka, Mahito Nakanishi, Hiromitsu Nakauchi, Makoto Otsu

Affiliations

  1. Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo , Tokyo, Japan ; Division of Stem Cell Processing/Stem Cell Bank, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo , Tokyo, Japan.
  2. Japan Science Technology Agency, Exploratory Research for Advanced Technology Nakauchi Stem Cell and Organ Regeneration Project , Tokyo, Japan.
  3. Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo , Tokyo, Japan ; Japan Science Technology Agency, Exploratory Research for Advanced Technology Nakauchi Stem Cell and Organ Regeneration Project , Tokyo, Japan.
  4. Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University , Kanazawa, Japan.
  5. Research Center for Stem Cell Engineering, National Institute of Advanced, Industrial Science and Technology , Tsukuba, Japan ; Laboratory of Gene Regulation, Faculty of Medicine, University of Tsukuba , Tsukuba, Japan.
  6. Research Center for Stem Cell Engineering, National Institute of Advanced, Industrial Science and Technology , Tsukuba, Japan.

PMID: 26682238 PMCID: PMC4674005 DOI: 10.1038/mtm.2015.46

Abstract

For the treatment of monogenetic hematological disorders, restoration of transgene expression in affected cell populations is generally considered to have beneficial effects. However, X-linked chronic granulomatous disease (XCGD) is unique since the appearance of functional neutrophils in the peripheral blood following hematopoietic stem cell gene therapy is transient only. One contributing factor could be the occurrence of detrimental effects secondary to ectopic gp91phox expression in neutrophils, which has not been formally demonstrated previously. This study uses iPSCs to model XCGD, which allows the process of differentiation to be studied intensely in vitro. Alpharetroviral vectors carrying a ubiquitous promoter were used to drive the "ectopic" expression of codon optimized gp91phox cDNA. In the mature fraction of neutrophils differentiated from transduced XCGD-iPSCs, cellular recovery in terms of gp91phox expression and reactive oxygen species production was abruptly lost before cells had fully differentiated. Most critically, ectopic gp91phox expression could be identified clearly in the developing fraction of the transduced groups, which appeared to correspond with reduced cell viability. It is possible that this impedes further differentiation of developing neutrophils. Therefore, affording cellular protection from the detrimental effects of ectopic gp91phox expression may improve XCGD clinical outcomes.

References

  1. Blood. 2009 Sep 24;114(13):2619-22 - PubMed
  2. Mol Ther. 2013 Jan;21(1):175-84 - PubMed
  3. Blood. 2011 Jan 20;117(3):953-9 - PubMed
  4. Science. 1997 Jun 13;276(5319):1719-24 - PubMed
  5. J Virol. 2010 Jul;84(13):6626-35 - PubMed
  6. Mol Ther. 2014 Aug;22(8):1472-83 - PubMed
  7. Stem Cells. 2013 Mar;31(3):488-99 - PubMed
  8. Jpn J Infect Dis. 2004 Oct;57(5):S27-8 - PubMed
  9. J Immunol. 2004 Jan 1;172(1):636-43 - PubMed
  10. J Cell Biol. 2010 Dec 13;191(6):1113-25 - PubMed
  11. Physiol Rev. 2007 Jan;87(1):245-313 - PubMed
  12. Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S123-31 - PubMed
  13. Stem Cells. 2007 Jul;25(7):1707-12 - PubMed
  14. Genomics Proteomics Bioinformatics. 2013 Oct;11(5):264-74 - PubMed
  15. Mol Med Today. 1996 Mar;2(3):129-35 - PubMed
  16. Science. 2000 Apr 28;288(5466):669-72 - PubMed
  17. J Biol Chem. 2011 Feb 11;286(6):4760-71 - PubMed
  18. Blood. 2009 Jun 25;113(26):6584-92 - PubMed
  19. Blood. 2011 May 26;117(21):5561-72 - PubMed
  20. Expert Opin Biol Ther. 2008 Dec;8(12):1955-62 - PubMed
  21. J Immunol Methods. 1995 Jan 13;178(1):89-97 - PubMed
  22. Science. 2004 Mar 5;303(5663):1532-5 - PubMed
  23. PLoS One. 2015 Feb 10;10(2):e0116410 - PubMed
  24. J Biol Chem. 1998 Mar 13;273(11):6575-81 - PubMed
  25. J Vis Exp. 2010 Feb 24;(36):null - PubMed
  26. Mol Ther. 2012 May;20(5):1022-32 - PubMed
  27. Medicine (Baltimore). 2000 May;79(3):170-200 - PubMed
  28. J Exp Med. 2010 Dec 20;207(13):2817-30 - PubMed
  29. Stem Cell Res. 2007 Nov;1(2):105-15 - PubMed
  30. Front Med. 2011 Dec;5(4):356-71 - PubMed
  31. Blood. 2008 Jun 1;111(11):5298-306 - PubMed
  32. J Biol Chem. 1998 Oct 23;273(43):27879-86 - PubMed
  33. J Exp Med. 2003 Dec 15;198(12):1829-39 - PubMed
  34. Mol Ther. 2013 Mar;21(3):648-61 - PubMed
  35. J Exp Med. 2008 Sep 29;205(10):2397-408 - PubMed
  36. Blood. 2012 Nov 1;120(18):3635-46 - PubMed
  37. Cell. 2007 Nov 30;131(5):861-72 - PubMed
  38. Stem Cells. 2012 Apr;30(4):599-611 - PubMed
  39. Nat Med. 2010 Feb;16(2):198-204 - PubMed
  40. PLoS One. 2012;7(7):e41007 - PubMed
  41. Mol Ther. 2011 Jan;19(1):28-35 - PubMed
  42. Blood. 2008 Jun 15;111(12):5704-11 - PubMed
  43. Mol Ther. 2012 May;20(5):1014-21 - PubMed

Publication Types